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The cause of the selective degeneration of nigrostri-
atal neurons in Parkinson disease (PD) has remained
largely unknown. Exceptions include rare missense
mutations in the alpha-synuclein gene on chromo-
some 4, a potentially pathogenic mutation affecting
the ubiquitin pathway, and mutations in the parkin
gene on chromosome 6. However, unlike classical PD,
the latter syndrome is not associated with the forma-
tion of typical Lewy bodies. In contrast, a biochemical
defect of complex I of the mitochondrial respiratory
chain has been described in a relatively large group of
confirmed PD cases. Recent cybrid studies indicate
that the complex I defect in PD has a genetic cause and
that it may arise from mutations in the mitochondrial
DNA. Sequence analysis of the mitochondrial genome
supports the view that mitochondrial point mutations
are involved in PD pathogenesis. However, although
mitochondria function as regulators in several known
forms of cell death, their exact involvement in PD has
remained unresolved. This is of relevance because
classical apoptosis does not appear to play a major
role in the degeneration of the parkinsonian nigra.
Key words: Apoptosis / Complex I / Mitochondrial DNA /
Neurodegeneration.
Introduction
Parkinson disease (PD) is a common neurological disorder
that affects more than 2% of the population older than 65
years. The disease is clinically characterized by a combi-
nation of the four cardinal symptoms, bradykinesia, rigidi-
ty, resting tremor and loss of postural reflexes. In addition,
affected individuals may be cognitively impaired. Due to
the significant overlap of clinical symptoms between PD
and several other neurodegenerative disorders, the de-
finitive diagnosis still rests on careful examination of the
brain and spinal cord post mortem. The most striking neu-
ropathological findings in PD include depigmentation of
the Substantia nigra, which results from a loss of pigment-
ed dopaminergic neurons, and the presence of Lewy bod-
ies in surviving nerve cells. Lewy bodies are also found
in related nuclei of the brain stem such as the Locus
coeruleus. By definition, Lewy bodies are a conditio sine
qua non for a definitive diagnosis of PD. They are best seen
in hematoxylin-eosin stained tissue sections and are im-
munoreactive for a number of proteins, including neurofil-
aments, ubiquitin and alpha-synuclein (vide infra). Their
role in PD is still unclear.
Evidence is accumulating that the clinico-pathological
‘entity’ PD in fact represents an etiologically heteroge-
neous group of disorders. Genetic as well as environmen-
tal factors, including oxidative cell damage and acceler-
ated aging, are likely to contribute to the multifactorial
etiology of this complex disease. Familial forms of PD are
rather uncommon (10 –15% of the cases) but rare mis-
sense mutations have been identified in the alpha-synu-
clein gene on chromosome 4 (Polymeropoulos et al.,
1997; Krüger et al., 1998). Although the frequency of
alpha-synuclein mutations is extremely low, this protein
now represents the most sensitive marker of Lewy bodies
also in idiopathic cases of the disease. Thus, alpha-synu-
clein is likely to have a central position in the pathway the
function of which is disturbed in PD. In addition, a poten-
tially pathogenic mutation affecting the ubiquitin pathway
(Leroy et al., 1998) and mutations in the parkin gene on
chromosome 6 (Kitada et al., 1998; Lücking et al., 1998)
have been described in some families. However, unlike
classical PD, the latter syndrome is not associated with
the formation of typical Lewy bodies. As indicated above,
the overwhelming majority of PD cases is sporadic and
lacks a family history making molecular genetic analyses
difficult. Availability of sufficient numbers of appropriate
controls for genetic studies, which need to be matched
not only for age and sex but also for ethnic background,
represents another problem. As a result, the finding of as-
sociations between several nuclear candidate genes and
PD has remained controversial. 
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Mitochondrial Dysfunction in
Parkinson Disease
First hints pointing to a contribution of mitochondria to PD
pathogenesis were obtained on the basis of a study by
Langston and colleagues in 1983 (Langston et al., 1983).
These authors observed that the neurotoxin MPTP (1-
methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) causes a
PD-like syndrome in humans. The toxin acts via inhibition
of complex I of the mitochondrial respiratory chain (Mc-
Naught et al., 1996). Subsequently, several studies report-
ed on a decrease of complex I activity in the Substantia
nigra of PD brains (Schapira et al., 1989, 1990; Mizuno et
al., 1989; Janetzky et al., 1994). In some patients, a de-
crease of complex I activity was also observed in platelets
(Krige et al., 1992; Benecke et al., 1993) and skeletal mus-
cle (Bindoff et al., 1991).
Complex I of the mitochondrial respiratory chain is lo-
calized at the inner mitochondrial membrane and forms
part of the oxidative phosphorylation (OXPHOS) system of
the mitochondrion, which is responsible for the produc-
tion of cellular ATP. The OXPHOS system consists of four
large enzyme complexes (complexes I, III, IV and V). Here,
electrons flow starting from NADH and FADH2 through
complexes I, III, and IV (respiratory chain) and are finally
transferred to O2 which is oxidized to H2O. The energy
released during oxidation is conserved by the vectorial
transport of protons from the mitochondrial matrix into
the intermembrane space. The resulting ‘chemiosmotic
gradient’ is then used by complex V, or ATPase, for the
synthesis of ATP (Figure 1). 
Complex I encompasses more than 40 protein subunits
with their majority being encoded by the nucleus. Howev-
er, the exact genomic location of most of these genes is
still unknown (Duncan et al., 1992; Kim et al., 1997; Russel
et al., 1997). In contrast, the genetic information for seven
polypeptide chains of mitochondrial complex I, termed
ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, is encoded
by the mitochondrial DNA (mtDNA) (Figure 1). The entire
sequence of the mitochondrial genome has been known
for almost 20 years (Anderson et al., 1981). This allows de-
tailed mutation analyses. mtDNA represents a double-
stranded, circular molecule of 16569 bp in length. There
are several copies of the mitochondrial genome per
organelle and several hundred mtDNA molecules per cell.
mtDNA codes for a total of 13 proteins which all are com-
ponents of the OXPHOS system in addition to two rRNA
molecules and 22 mitochondrial tRNAs (Wallace, 1992).
There are several important differences between mito-
chondrial and nuclear genetics. mtDNA is transmitted ex-
clusively through the maternal line. Furthermore, the mu-
tation rate of mtDNA is approximately 10-20 times higher
than that of nuclear DNA. Reasons for this include an in-
sufficiency of the mitochondrial DNA repair system, lack of
protective histone-like proteins and the physical proximity
of the mitochondrial chromosome to the OXPHOS system
which generates oxygen radicals even in its normal state.
Due to the high copy number of the mtDNA, varying
amounts of normal and mutated mtDNA species can co-
exist in the same cell. This state is referred to as hetero-
plasmy. During cell division in mitotically active tissues,
mitochondria segregate randomly into daughter cells.
This will create differences in the proportion of mutant
mtDNA between different cells and tissues. Thus, in the
case of a heteroplasmic mtDNA mutation, expression of
its clinical phenotype may depend on tissue specific
thresholds. Therefore, mitochondrial mutations are ideally
studied in the anatomical region of their postulated patho-
genic effect, i. e., the Substantia nigra in PD.
Recent studies indicate that there is, in fact, a contribu-
tion of mtDNA to PD pathogenesis. Studies on PD families
have demonstrated a matrilineal pattern of inheritance in
some instances (Wooten et al., 1997; Swerdlow et al.,
1998). In addition, two independent groups using mtDNA-
less human 0 cells repopulated with mitochondria de-
rived from platelets of PD patients and controls (Swerdlow
et al., 1996; Gu et al., 1998; Figure 2) were able to show
that the parkinsonian complex I defect is transmittable by
mtDNA. These same authors reported a mean decrease of
20 –25% in complex I activity and increased oxygen radi-
cal production in PD cybrid cells compared with controls.
Moreover, studying PD families, cybrid cell lines contain-
ing mtDNA from maternal descendants showed lower
complex I activity, increased oxygen radical formation and
morphologically abnormal mitochondria (Swerdlow et al.,
1996). Corresponding results were also obtained on sam-
Fig.1 Schematic Drawing of the Mitochondrial Respiratory Chain and Oxidative Phosphorylation System (OXPHOS).
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ples from symptomatic PD patients and asymptomatic
young maternal siblings (Swerdlow et al., 1998). In con-
trast, no mitochondrial transmission of the complex I de-
fect was found in cybrids generated with platelets from
patients affected by dystonia (Tabrizi et al., 1998). Thus,
the mitochondrial complex I defect in PD is likely to be due
to an mtDNA abnormality in a subset of PD patients. Its
postulated mechanism of action is an elevated production
of oxygen radicals leading to an increased susceptibility 
of nigra neurons to cell death. The PD Substantia nigra is
especially sensitive to oxygen radical damage because 
its level of glutathione is reduced (Sian et al., 1994). In 
addition, the neurotransmitter metabolism of dopamin-
ergic neurons produces reactive oxygen species even
under normal conditions. The toxicity of the latter may be
further increased by the large amounts of iron which are
present in the parkinsonian Substantia nigra (Hartley et al.,
1993). 
Molecular Genetic Analysis of mtDNA
in Parkinson Disease
High throughput analysis of the mitochondrial genome in
PD is in its infancy. Efforts to elucidate the genetic basis
of the parkinsonian complex I defect by systematic se-
quencing of the mitochondrial genome have so far been
confined to little more than 30 cases worldwide. Early
studies employing Southern blotting had failed to detect
deletions of the mtDNA genome in PD (Lestienne et al.,
1990). Great care has to be taken when interpreting indi-
vidual studies because not all groups have used DNA iso-
lated from the Substantia nigra and, more importantly,
from neuropathologically verified cases. In addition, there
is firm evidence now that the frequency of certain mtDNA
sequence variants may vary greatly depending on ethnic
background. 
The so-called ‘common deletion’ of mtDNA which spans
4977 bp and which removes appx. 40% of complex I
genes has been implicated in PD. The concentration of
this mtDNA species has been suggested to increase in the
parkinsonian nigra and to be responsible for the observed
biochemical defect of complex I (Ozawa et al., 1990).
However, we and others (Mann et al., 1992; Kösel et al.,
1997a) have been unable to confirm this finding and rather
believe that the overall moderate increase (5% vs. control)
in the amount of mtDNA carrying the ‘common deletion’
probably represents an age-related phenomenon. 
Ikebe and coworkers sequenced DNA which had been
extracted from the striatum of five PD brains. Although
there were no specific point mutations among the patients
in contrast to several neuromuscular disease cases, they
found several point mutations in each brain which should
result in a significant change of the gene product. They
concluded that some of the mutations may be risk factors
for PD which increase the susceptibility of nigra neurons to
oxidative damage (Ikebe et al., 1995). The Wallace group
(Brown et al., 1996) has completely sequenced mtDNA
from four patients three of whom, however, exhibited neu-
ropathological changes of PD and Alzheimer disease at
the same time. The single ‘PD only’ patient carried two
novel sequence variants. One was detected at nucleotide
position 15851 of the cytochrome b (cytb) gene and
another one at position 1709 of the gene encoding the 
16S rRNA. The ‘PD + Alzheimer’ patients also harbored
mtDNA sequence changes which were considered likely
to contribute to the observed neuropathology (Brown et
al., 1996). Interestingly, one of these patients carried the
mtDNA 4336 A/G mutation which affects the mitochon-
drial tRNA for glutamine. Other studies have shown that
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Fig.2 Generation of Cybrids using 0 Cells (Which Lack mtDNA) and Platelets of PD Patients Who Carry mtDNA Point Mutations to Study
Functional Aspects of these Mutations.
(A) 0 cells are generated by incubation with ethidium bromide (EtBr). EtBr removes mtDNA from the cells which are then cultured in an uri-
dine-supplemented medium. Following the fusion of 0 cells with the patients’ platelets, the mitochondrial functional phenotype of the pa-
tients is expressed by the cybrid cell line. (B) Confocal image of a cybrid cell. Platelet mitochondria and mitochondria of the 0 cell were la-
beled with MitoTracker red and green, respectively. Scale bar: 15 m.
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this sequence variant represents a risk factor for both PD
and Alzheimer disease (Shoffner et al., 1993; Egensperger
et al., 1997).
To further clarify the contribution of mitochondrial se-
quence variation to PD pathogenesis we have sequenced
all mitochondrial complex I genes as well as the mitochon-
drial tRNA genes in 22 (20) cases of neuropathologically
confirmed PD (Kösel et al., 1998; Grasbon-Frodl et al.,
1999). In all cases, DNA extracted from the Substantia ni-
gra of autopsy brains was used. We found seven novel
missense mutations in complex I subunit genes ND1
(3992 C/T, 4024 A/G), ND4 (11253 T/C, 12084 C/T), ND5
(13711 G/A, 13768 T/C) and ND6 (14582 T/C). In addition,
eight known missense mutations including three sec-
ondary LHON mutations (4216 T/C, 4917 A/G, 13708 G/A)
as well as 43 synonymous polymorphisms, among them
20 novel sequence variants, were detected in complex I
genes. Subsequent computer analysis of the novel muta-
tions using secondary structure prediction indicated that
at least one of them, a T/C transition at nucleotide position
11253 which changes a conserved isoleucine residue into
threonine, is likely to contribute to PD pathogenesis. Fur-
thermore, two new point mutations were detected in the
mitochondrial tRNA genes for threonine (15950 G/A) and
proline (15965 T/C). Both sequence changes alter func-
tionally relevant sites of the respective tRNA molecule
(aminoacyl acceptor stem, TpsiC). Six known other se-
quence variants were detected in tRNA genes including
the abovementioned 4336 A/G mutation (Grasbon-Frodl
et al., 1999). 
The results of our sequencing studies indicate that the
majority of all idiopathic PD cases are unlikely to be due to
sequence variation in mitochondrial complex I genes.
Nevertheless, mutations in mitochondrially encoded com-
plex I and/or tRNA genes (one patient showed both) may
well play a pathogenic role in a sizeable portion of PD
patients, considering the high frequency of the disease.
Our findings are fully in line with the observation that a
complex I defect is present in between 10 –30% of PD pa-
tients (A.H.V. Schapira, personal communication). In addi-
tion, mutations in nuclear complex I genes could also con-
tribute to PD. Hattori and co-workers, for instance, have
reported on a point mutation in the 24 kDa subunit gene
(NDUFV2) which appears to represent a risk factor for PD
in the homozygous state (Hattori et al., 1998). 
In order to combine systematic sequencing and func-
tional analyses of mtDNA mutations, we have begun to an-
alyze five pairs of monozygotic twins with a longitudinal di-
agnosis of PD using a cybrid system (Vieregge et al., 1999;
Kösel et al., in preparation). Four twin pairs are presently
still discordant for PD. It is of interest that five novel se-
quence variants were detected in the mitochondrial genes
encoding complex I in four of the pairs. Two of these mis-
sense mutations affect nucleotide positions 4924 and
10192, respectively. Both sequence variants were found
in the affected as well as the unaffected twin of each pair
but were absent in controls. Cybrids generated by fusion
of 0 cells with platelet mitochondria of the PD patients are
currently being propagated in culture (Figure 2). Biochem-
ical analyses will show whether the newly discovered mi-
tochondrial point mutations are of functional relevance. 
Contribution of Mitochondrial Dysfunction
to Nigral Cell Death
It is becoming increasingly evident that one important new
function of mitochondria lies in the control of cell death. In
fact, mitochondria have been suggested by some authors
to serve as the ‘cellular centers of death control’ (Hirsch et
al., 1997; Lemasters et al. 1998; Susin et al., 1998). Some
groups have entertained the possibility that apoptosis
may be the cell death pathway underlying the neuronal
demise which occurs in the parkinsonian nigra. In particu-
lar, staining results obtaind with the so-called TUNEL
technique, which allows visualization of fragmentation of
DNA, have been interpreted as representing signs of
apoptotic cell death in melanized neurons of the Sub-
stantia nigra (Mochizuki et al., 1996; Anglade et al., 1997;
Tompkins et al., 1997). Surprisingly, these changes were
observed even in very late stages of the disease. Tompkins
et al. (1997), in contrast, could not rule out that some
necrosis had taken place in addition to apoptosis. 
We have applied labeling of fragmented DNA by the
TUNEL method to 22 neuropathologically verified cases
of PD which had been genotyped for mtDNA mutations
(Kösel et al., 1997b). Classical signs of apoptosis such as
chromatin condensation in association with nuclear frag-
mentation and the formation of apoptotic bodies were
consistenly absent from nigra neurons, whereas mild
apoptosis-like changes could be observed in some glial
cells. Our results are thus in line with the study of Banati
and co-workers (1998) who also failed to detect evidence
of apoptosis in the parkinsonian Substantia nigra. A third
study had previously arrived at the same conclusion (Dra-
gunow et al., 1995). Furthermore, PD usually develops
over many years whereas apoptosis is a very rapid
process. Thus, we conclude that apoptosis is not a typical
autopsy finding in PD. We have proposed the new term
aposklesis (‘withering’) to name this non-physiological
mode of cell death which appears to take a slow course
and which is associated with biochemical DNA but not
morphological chromatin fragmentation (Graeber et al.,
1999). However, heterogeneity of cell death mechanisms
may be envisioned in a very common disease such as PD.
In conclusion, PD does not represent a single disease
entity but comprises a genetically heterogeneous group
disorders. Recent cybrid studies have shown that the
complex I defect in PD is genetic and that it can arise from
mtDNA. Systematic sequence analysis of the mitochon-
drial genome further indicates that mutations of respirato-
ry chain complex I are present in a subset of PD patients.
However, the exact mechanism which kills nigra neurons
remains unknown. 
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